Effect of Sleep Extension on Ceramides in People With Overweight and Obesity
The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g…
Conditions studied
Lifestyle Factors, Overweight and Obesity, Insulin Sensitivity, Eating Habit, Sleep Hygiene, Type 2 Diabetes, Sleep, Sleep Deprivation, Insufficient Sleep Syndrome
About this study
The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).
Interventions
- Behavioral: Sleep Extension Intervention — Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
Primary outcomes
- Total Plasma Ceramides (Immediately after the intervention)
- Insulin Sensitivity (Immediately after the intervention)
Eligibility information
Study locations
- College of Health Research Complex--University of Utah, Salt Lake City, Utah 84112 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.